<DOC>
	<DOCNO>NCT00794508</DOCNO>
	<brief_summary>Severe combine immune deficiency ( SCID ) may result inherited deficiency enzyme adenosine deaminase ( ADA ) . Children ADA-deficient SCID often die infection infancy , unless treat either bone marrow transplant ongoing injection PEG-ADA ( Adagen ) enzyme replacement therapy . Successful BMT require availability match sibling donor great success , treatment use bone marrow less-well match donor may higher rate complication . PEG-ADA may restore sustain immunity many year , expensive require injection 1-2 time per week ongoing basis . This clinical trial evaluate efficacy safety alternative approach , add normal copy human ADA gene stem cell bone marrow patient ADA-deficient SCID . Eligible patient ADA-deficient SCID , lack match sibling donor , eligible meet entry criterion adequate organ function absence active infection follow informed consent process . Bone marrow collect back pelvis patient process laboratory isolate stem cell add human ADA gene use retroviral vector . The patient receive moderate dosage busulfan , chemotherapy agent eliminate bone marrow stem cell patient , `` make space '' gene-corrected stem cell grow give back IV . Patients follow two year assess potentially beneficial effect procedure function immune system assess possible side-effects . This gene transfer approach may provide good safer alternative treatment patient ADA-deficient SCID .</brief_summary>
	<brief_title>MND-ADA Transduction CD34+ Cells From Children With ADA-SCID</brief_title>
	<detailed_description>The propose study population affect adenosine deaminase-deficient severe combine immune deficiency ( ADA-SCID ) , autosomal recessive congenital immune deficiency . The basis propose study ( product ) retroviral-mediated transduction autologous , bone marrow derive CD34+ hematopoietic progenitor cell MND-ADA retroviral vector 5 day cell processing period . Transduction follow infusion wash cell subject receive enzyme replacement therapy Polyethylene-conjugated ADA ( PEG-ADA , ADAGEN7 ) PEG-ADA injection discontinue , undergone bone marrow cytoreductive therapy single non-ablative treatment course Busulfan . The dose cell infuse determine patient-to-patient variation number progenitor available individual patient . Statistical analyse post-infusion help determine dose-response number cell infused level engraftment result level immune reconstitution . Following cellular infusion , primary clinical end-point absolute number T B lymphocytes contain transduce ADA gene quantitative , real-time PCR analysis . Measurement blood mononuclear cell ADA enzyme level analyze . Based degree mark lymphocyte granulocyte , selective advantage lymphocyte may gauge . Subjects monitor development clonal proliferation , 15 year plan require FDA . One major aim study see subject remain PEG-ADA maintain protective immunity population transduce lymphocyte arise transduced progenitor . If sufficient gene-modified cell result , PEG-ADA enzyme replacement therapy permanently discontinue , advantage therapeutic approach may change standard care patient .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Severe Combined Immunodeficiency</mesh_term>
	<mesh_term>Adenosine</mesh_term>
	<criteria>1 . Children &gt; 1.0 month age diagnosis ADAdeficient SCID base : Confirmed absence ( &lt; 3 % normal level ) ADA enzymatic activity peripheral blood ( neonate ) umbilical cord erythrocytes and/or leukocyte , culture fetal cell derive either chorionic villus biopsy amniocentesis , prior institution enzyme replacement therapy . AND Evidence severe combine immunodeficiency base either : Family history first order relative ADA deficiency clinical laboratory evidence severe immunologic deficiency , OR Evidence severe immunologic deficiency subject base lymphopenia ( absolute lymphocyte count &lt; 200 ) severely decrease T lymphocyte blastogenic response phytohemagglutinin ( deltaCPM &lt; 5,000 ) , prior institution immune restorative therapy . OR Fulfillment criterion : A addition evidence genetic mutation affect ADA gene determine CLIA certify laboratory clinical evidence combine immunodeficiency base lymphopenia ( absolute lymphocyte count &lt; 2SD agematched control value ) hypogammaglobulinemia ( &lt; 2SD agematched control value ) lack specific antibody response vaccination . In addition , patient eligible criterion , must present clinical history indicate lifethreatening illness characterize increased frequency and/or severity infection result hospitalization and/or administration intravenous antibiotic , bacterial opportunistic infection . 2 . Ineligible allogeneic ( matched sibling ) bone marrow transplantation ( BMT ) : Absence medically eligible HLAidentical sibling normal immune function may serve allogeneic bone marrow donor . 3 . Written inform consent accord guideline Institutional Review Board ( IRB ) University California Los Angeles ( UCLA ) . This study also open delayed/late onset ADAdeficient patient fulfill criterion 1 , 2.A , 3 receive PEGADA treatment invite discuss alternative treatment option physician connect protocol . 1 . Age less 1 month 2 . Hematologic . Anemia ( hemoglobin &lt; 10.5 mg/dl &lt; 2 year age , &lt; 11.5 &gt; 2 year age , normal serum iron study ) . b. Neutropenia i. absolute granulocyte count &lt; 500/mm3 ii . absolute granulocyte count 500999/mm3 ( 1 month 1 year age ) 5001499/mm3 ( &gt; 1 year age ) ] bone marrow aspirate biopsy show myelodysplasia gross abnormality . c. Thrombocytopenia ( platelet count 150,000/mm3 , age ) . d. PT PTT &gt; 2X normal . e. Cytogenetic abnormality peripheral blood , cell collect amniocentesis , diagnose utero . 3 . Infectious . Evidence active opportunistic infection infection HIV1 , hepatitis B , CMV parvovirus B 19 DNA PCR time assessment . 4 . Pulmonary 1 . Resting O2 saturation pulse oximetry &lt; 95 % . 2 . Chest xray indicate active progressive pulmonary disease . 5 . Cardiac 1 . Abnormal electrocardiogram ( EKG ) indicate cardiac pathology . 2 . Uncorrected congenital cardiac malformation . 3 . Active cardiac disease , include clinical evidence congestive heart failure , cyanosis , hypotension . 6 . Neurologic 1 . Significant neurologic abnormality examination . 2 . Uncontrolled seizure disorder . 7 . Renal 1 . Renal insufficiency : serum creatinine &gt; = 1.2 mg/dl , &gt; = 3+ proteinuria . 2 . Abnormal serum sodium , potassium , calcium , magnesium , phosphate grade III IV Division AIDS Toxicity Scale . 8 . Hepatic/GI : 1 . Serum transaminases &gt; 5X normal . 2 . Serum bilirubin &gt; 3.0 mg/dl . 3 . Serum glucose &gt; 250mg/dl . 4 . Intractable severe diarrhea . 9 . Oncologic ( see below* ) 1 . Evidence active malignant disease dermatofibrosarcoma protuberans ( DFSP ) 2 . Evidence DFSP expect require antineoplastic therapy within 5 year follow infusion genetically correct cell 3 . Evidence DFSP expect life limit within 5 year follow infusion genetically correct cell 10 . Known sensitivity Busulfan 11 . General 1 . Expected survival &lt; 6 month . 2 . Pregnant . 3 . Major congenital anomaly . 4 . Medically eligible HLAmatched sibling . 5 . Other condition opinion P.I . coinvestigators , contraindicate infusion transduce cell indicate patient 's inability follow protocol .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Severe Combined Immune Deficiency</keyword>
	<keyword>Adenosine Deaminase Deficiency</keyword>
	<keyword>Gene Therapy</keyword>
	<keyword>Hematopoietic Stem Cells</keyword>
	<keyword>Retroviral Vector</keyword>
	<keyword>ADA-deficient SCID</keyword>
</DOC>